Impax Laboratories Inc (NASDAQ:IPXL) – Piper Jaffray issued their Q2 2018 earnings per share estimates for shares of Impax Laboratories in a report issued on Monday, April 16th. Piper Jaffray analyst D. Amsellem anticipates that the specialty pharmaceutical company will earn $0.26 per share for the quarter. Piper Jaffray also issued estimates for Impax Laboratories’ Q3 2018 earnings at $0.29 EPS, Q4 2018 earnings at $0.32 EPS, FY2018 earnings at $1.10 EPS, Q1 2019 earnings at $0.31 EPS, Q2 2019 earnings at $0.35 EPS, Q3 2019 earnings at $0.39 EPS, Q4 2019 earnings at $0.45 EPS, FY2019 earnings at $1.50 EPS and FY2020 earnings at $1.85 EPS.
Impax Laboratories (NASDAQ:IPXL) last issued its quarterly earnings results on Thursday, March 1st. The specialty pharmaceutical company reported $0.11 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.01). The business had revenue of $182.90 million for the quarter, compared to the consensus estimate of $199.13 million. Impax Laboratories had a positive return on equity of 10.42% and a negative net margin of 60.49%. Impax Laboratories’s revenue was down 7.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.16 earnings per share.
Several other research firms also recently commented on IPXL. Canaccord Genuity set a $19.00 price objective on Impax Laboratories and gave the company a “hold” rating in a report on Thursday, March 1st. BMO Capital Markets raised their price target on Impax Laboratories from $18.00 to $20.00 and gave the company a “market perform” rating in a report on Monday, April 16th. Zacks Investment Research raised Impax Laboratories from a “hold” rating to a “buy” rating and set a $23.00 price target for the company in a report on Friday, March 16th. Cantor Fitzgerald set a $35.00 price target on Impax Laboratories and gave the company a “buy” rating in a report on Thursday, March 1st. Finally, BidaskClub downgraded Impax Laboratories from a “hold” rating to a “sell” rating in a report on Friday, February 16th. Four research analysts have rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $21.15.
NASDAQ IPXL opened at $19.90 on Thursday. The company has a market capitalization of $1,492.21, a PE ratio of 31.59, a P/E/G ratio of 0.92 and a beta of 1.17. The company has a debt-to-equity ratio of 4.11, a current ratio of 1.96 and a quick ratio of 1.52. Impax Laboratories has a 12 month low of $12.70 and a 12 month high of $25.70.
Institutional investors and hedge funds have recently bought and sold shares of the company. Xact Kapitalforvaltning AB acquired a new stake in shares of Impax Laboratories during the fourth quarter worth $198,000. BlueCrest Capital Management Ltd acquired a new stake in shares of Impax Laboratories during the fourth quarter worth $336,000. Envestnet Asset Management Inc. lifted its holdings in shares of Impax Laboratories by 470.9% during the fourth quarter. Envestnet Asset Management Inc. now owns 20,581 shares of the specialty pharmaceutical company’s stock worth $343,000 after buying an additional 16,976 shares in the last quarter. Teacher Retirement System of Texas acquired a new stake in shares of Impax Laboratories during the fourth quarter worth $393,000. Finally, Commerce Bank lifted its holdings in shares of Impax Laboratories by 112.7% during the fourth quarter. Commerce Bank now owns 24,375 shares of the specialty pharmaceutical company’s stock worth $406,000 after buying an additional 12,915 shares in the last quarter. 90.40% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Research Analysts Offer Predictions for Impax Laboratories Inc’s Q2 2018 Earnings (IPXL)” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/21/research-analysts-offer-predictions-for-impax-laboratories-incs-q2-2018-earnings-ipxl.html.
Impax Laboratories Company Profile
Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.
Receive News & Ratings for Impax Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.